This invention relates generally to compositions for making anellovectors and uses thereof. For instance, the disclosure provides compositions and methods for using insect cells to produce Anellovirus proteins, e.g., ORF1.

This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.

This invention relates generally to anellosomes and compositions and uses thereof.

This invention relates generally to pharmaceutical compositions and preparations of curons and uses thereof.

This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.

This invention relates generally to pharmaceutical compositions and preparations of curons and uses thereof.

This invention relates generally to compositions for making and administering anellovectors and uses thereof.

This invention relates generally to pharmaceutical compositions and preparations of curons and uses thereof.

This invention relates generally to anellovectors and compositions and uses thereof.

The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of an proteins. The compositions may also be used to detect amyloid.